2022 World Conference on Lung Cancer (Posters)-P1.15-02. Plasma microRNAs Modulation in Advanced NSCLC Patients Receiving Single Agent Immune Checkpoint Inhibitors

Pdf Summary

Researchers conducted a study to investigate whether specific circulating microRNA (miRNA) features are associated with clinical outcomes in patients with advanced non-small cell lung cancer (NSCLC) treated with single-agent immune checkpoint inhibitors (ICI). The study aimed to improve the prediction of survival and identify features that change due to treatment response and/or disease progression. <br /><br />The study enrolled 211 patients with advanced NSCLC and analyzed baseline and longitudinally collected plasma samples using the 24 miRCURY LNA Lung Cancer Custom Panel. The researchers used microRNA ratios in logarithmic scale instead of single microRNA features due to the not Gaussian distribution of microRNA data. <br /><br />The results showed that including microRNA in the model composed of nine clinical variables improved the prediction of 1-year overall survival (OS) probability compared to using only clinical variables. The mean absolute error decreased from 0.108 to 0.013. Similar results were observed when considering 6-month progression-free survival (PFS) as the endpoint. <br /><br />The researchers identified specific microRNA features associated with response to treatment. However, there were no main differences in microRNA expression between time points of response and disease progression. <br /><br />In conclusion, circulating microRNA features at baseline and during treatment may serve as an easily evaluable tool to help clinicians select patients and monitor response to single-agent ICI in advanced NSCLC. The study highlights the potential of microRNA as additional markers to personalize therapy and improve the prediction of survival outcomes in NSCLC patients receiving immune checkpoint inhibitors.

Asset Subtitle

Claudia Proto, Italy

Meta Tag

Speaker Claudia Proto, Italy

Topic Metastatic Non-small Cell Lung Cancer – Immunotherapy

Keywords

circulating microRNA

clinical outcomes

non-small cell lung cancer

immune checkpoint inhibitors

prediction of survival

treatment response

microRNA ratios

progression-free survival

microRNA expression

personalize therapy